Phenylalanine

Phenylalanine

SCHEMBL208389

CC(C)C[C@H](N)C(=O)O.N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.76
ALPI P09923 1/20 0.76
PKM P14618 1/20 0.76
PTGS1 P23219 1/20 0.76
XIAP P98170 1/20 0.76
ANPEP P15144 2/20 0.66
RNPEP Q9H4A4 2/20 0.66
DNPEP Q9ULA0 2/20 0.66
SLC1A3 P43003 3/20 0.65
SLC1A2 P43004 3/20 0.65
SLC1A1 P43005 2/20 0.65
LTA4H P09960 1/20 0.61
SLC15A1 P46059 1/20 0.51
NOS3 P29474 1/20 0.51
NOS1 P29475 1/20 0.51
NOS2 P35228 1/20 0.51
TAAR1 Q96RJ0 2/20 0.50
MAOA P21397 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylalanine SCHEMBL2634732 1.00 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
D-Phenylalanine SCHEMBL10775923 1.00 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL27551454 1.00 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL31087886 1.00 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL10945389 1.00 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL28157585 1.00 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL208388 1.00 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL15323535 0.98 SLC7A5 (0.73) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL15323532 0.98 SLC7A5 (0.73) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL8532962 0.97 SLC7A5 (0.71) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117877567-A Metabolic marker for clinical early diagnosis of smoke disease and application thereof 河南省人民医院 2024-04-12 CN claimed
CN-117723757-A Metabolic markers for diagnosing acute myocardial infarction 哈尔滨脉图精准技术有限公司 2024-03-19 CN claimed
CN-117269499-A Metabolic marker combinations for predicting skin barrier levels and uses thereof 麦吉丽生物科技有限公司 2023-12-22 CN claimed
EP-3990654-B1 MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED AROMATIC HYDROCARBONS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-10-04 EP claimed
EP-3990654-A1 MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED HYDROCARBONS Covestro Intellectual Property GmbH & Co. KG (DE) 2022-05-04 EP claimed
CN-112641956-A Preparation and application of peptide-metal-drug self-assembly nanoparticles for resisting Alzheimer's disease 福州大学 2021-04-13 CN claimed
EP-3762489-A1 METHODS AND COMPOSITIONS FOR LIVE CELL ANALYSIS OF INTRACELLULAR ATP Essen Instruments, Inc. d/b/a Essen BioScience, Inc. (US) 2021-01-13 EP claimed
WO-2020260119-A1 MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED HYDROCARBONS COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2020-12-30 WO claimed
CN-111183219-A Methods and compositions for viable cell analysis of intracellular ATP 埃森仪器公司DBA埃森生物科学公司 2020-05-19 CN claimed
EP-3544992-A1 G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS The Regents of The University of California (US) 2019-10-02 EP claimed
US-20030049683-A1 Immunoglobulin for use in human therapeutics and diagnostics ALEXION PHARMACEUTICAL, INC. 2003-03-13 US claimed
EP-1084137-A1 PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2001-03-21 EP claimed
WO-1999064442-A1 PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) 1999-12-16 WO claimed
EP-0932684-A2 3' GENOMIC PROMOTER REGION AND POLYMERASE GENE MUTATIONS RESPONSIBLE FOR ATTENUATION IN VIRUSES OF THE ORDER DESIGNATED MONONEGAVIRALES AMERICAN CYANAMID COMPANY (US) 1999-08-04 EP claimed
WO-1998013501-A2 3' GENOMIC PROMOTER REGION AND POLYMERASE GENE MUTATIONS RESPONSIBLE FOR ATTENUATION IN VIRUSES OF THE ORDER DESIGNATED MONONEGAVIRALES AMERICAN CYANAMID COMPANY (US) 1998-04-02 WO claimed
WO-1995033764-A1 ORAL COMPOSITIONS COMPRISING A NOVEL TRIPEPTIDE THE PROCTER & GAMBLE COMPANY (US) 1995-12-14 WO claimed
CN-1068335-A C type hepatitis diagnosis preparation and vaccine LUCKY LTD (KR) 1993-01-27 CN claimed
EP-0076557-B1 PEPTIDES AND PSEUDOPEPTIDES IN WHICH THE N TERMINUS BEARS TWO SUBSTITUENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-11-13 EP claimed
US-4421744-A OPIATE RECEPTOR ANTAGONISTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-12-20 US claimed
EP-0076557-A2 Peptides and pseudopeptides in which the N terminus bears two substituents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-04-13 EP claimed